2025 Performance
Business Highlights
Annual Performance Trend for the Past 5 Years | Annual Performance Trend for the Past 5 Years |
|---|---|
2025 Sales Ratio  | 2025 Sales Ratio  |
Export Performance1) (Non-consolidated)
KRW 209.7 billion (2025)
Category | Unit | 2023 | 2024 | 2025 |
Domestic Sales | KRW 100M | 8,853 | 9,123 | 9,369 |
Exports | 2,117 | 2,018 | 2,097 |
2025 Export Sales Percentage by Region  | 2025 Sales Proportion by Product Category  |
|---|
Outpatient Prescription PerformanceKRW 1,015.0 billion (No. 1 in the domestic pharmaceutical industry for 8 consecutive years)  * Source: UBIST D1 | Product Sales Proportion (vs. Domestic Sales)97.5%  *Product sales: Sales revenues generated by the sale of products developed in-house and manufactured in domestic factories. |
|---|
Status of Blockbuster Products
20 products (No. 1 among domestic pharmaceutical companies) | Criterion: Pharmaceutical Bio Data Analysis Solution UBIST D1 Sales | ||||
Product | Indication | 2025 Sales | Product | Indication | 2025 Sales |
Rosuzet | Dyslipidemia | 2,279 | Hyalu Mini | Dry eye syndrome | 186 |
Amosartan | Hypertension | 903 | Monterizine | Asthma/Allergic Rhinitis | 178 |
Esomezol | Gastroesophageal Reflux Disease (GERD) | 610 | Mirabek | Overactive Bladder | 174 |
Hanmi Tams | Benign Prostatic Hyperplasia (BPH) | 458 | Hanmi Omega | Dyslipidemia | 142 |
PalPal | Erectile Dysfunction | 368 | Rabon D | Osteoporosis | 140 |
Amosartan Plus | Hypertension | 309 | Dapalon family | Diabetes | 125 |
Amodipin | Hypertension | 247 | Amosartan XQ | Hypertension/Dyslipidemia | 125 |
Naxozol | Anti-inflammatory Analgesics | 243 | Rovelito | Hypertension/Dyslipidemia | 109 |
Gugu | Erectile Dysfunction | 226 | Amosartan Q | Hypertension/Dyslipidemia | 109 |
Pidogul | Antithrombotic Agents | 205 | Fenocid | Dyslipidemia | 104 |
Sales and Production Performance | Unit: KRW 1M / Consolidated Basis | |||||
Category | Business area | Type | Sales | Type | Production | Production |
Domestic | Pharmaceuticals | Tablets | 585,981 | Tablets (Amosartan, etc.) | 181,613 | 183,360 |
Capsules | 214,165 | Soft Capsules (Esomezol, etc.) | 78,946 | 75,522 | ||
Injectables | 46,130 | Injectables (Triaxone, etc.) | 69,947 | 70,737 | ||
Syrups | 274,651 | Syrups (Maxibupen, etc.) | 88,634 | 65,838 | ||
Powders | 58,446 | Powders (Medilac-bebe, etc.) | 16,692 | 12,307 | ||
Pharmaceutical Ingredients | 89,429 | Pharmaceutical Ingredients (CTO, etc.) | 76,531 | 104,726 | ||
Other | 151,374 | Other | 69,442 | 65,892 | ||
Other | Contract Manufacturing, etc. | 6,612 | ||||
Exports | Product | Injectables, etc. | 74,217 | Injectables (e.g., Tazime Inj.) | 3,173 | 3,209 |
Merchandise | Pharmaceutical Ingredients (APIs), etc. | 112,315 | Soft Capsules, etc. (e.g., Coza XQ) | 8,021 | 8,112 | |
Technology Export, etc. | Technology Export/Service Revenue | 26,977 | Other | 13,810 | 13,965 | |
Total | Domestic Sales | 1,426,788 | Domestic Sales | 581,806 | 578,382 | |
Exports | 213,509 | Exports | 25,004 | 25,286 | ||
Intercompany Transactions | -92,766 | |||||
Total | 1,547,531 | Total | 606,809 | 603,668 | ||
ESG Highlights
Key ESG Assessment Results
ESG Rating Agency | 2025 Results | Meaning |
|---|---|---|
 | DJBIC KOREA | The DJBIC (Dow Jones Best-In-Class) index is a global index that comprehensively evaluates a company's economic, environmental, and social sustainability. DJBIC KOREA selects the top 30% of domestically listed companies with excellent sustainability. |
 | SILVER (Consolidated) | EcoVadis is a global supply chain sustainability rating agency that assesses companies in areas such as environment, labor & human rights, ethics, and sustainable procurement. |
 | C grade | CDP (Carbon Disclosure Project) is a global initiative that assesses companies worldwide on their climate change responses and carbon emission reduction efforts. |
 | B grade | The Korea Institute of Corporate Governance and Sustainability (KCGS) is a leading domestic ESG rating agency that evaluates companies' environmental, social, and governance sectors to assign ESG grades. |
 | BB grade | SUSTINVEST is a major domestic ESG rating agency that comprehensively evaluates companies' environmental (E), social (S), and governance (G) factors to assign grades. |
Participation in Key Initiatives
Initiatives | Meaning |
|---|---|
 | The UN Global Compact (UNGC) is a UN-led global initiative aimed at strengthening corporate sustainability and social responsibility. Hanmi Pharmaceutical adheres to the UNGC's 10 principles (human rights, labor, environment, anti-corruption) and strives to practice global sustainable management. |
 | TCFD is a global initiative that encourages companies to analyze and disclose the financial impacts of climate change. Hanmi Pharmaceutical systematically manages climate change-related financial risks and has established a climate change response strategy for sustainable growth, aligning with global standards. |
 | BNBP is a cooperation platform that supports companies in promoting sustainable management considering biodiversity. Hanmi Pharmaceutical actively practices biodiversity protection and sustainable management activities. |
Major Awards by Year
Year | Content |
|---|---|
2019 | Global Standard Management Awards, 1st Place in Sustainable Management |
2020 | Korea Sustainability Index, 1st Place in Pharmaceutical Sector |
2021 | Korea Sustainability Index, 1st Place in Pharmaceutical Sector (2 consecutive years) |
2022 | Korea Sustainability Index, 1st Place in Pharmaceutical Sector (3 consecutive years) |
2023 | Korea Sustainability Index, 1st Place in Pharmaceutical Sector (4 consecutive years) |
2024 | National Quality Management Convention, Prime Minister's Commendation in Sustainable Management |
